Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tdinovo who wrote (10133)	10/25/1997 9:35:00 PM
From: lavalamp	Read Replies (1) \| Respond to of 32384

tdinovo, check out the profile date and the fact that it takes 2 weeks to get to post and you may be decide that someone posting here now was posting previouly (but must have been someone else). there is a list of several people that come to mind.:>

To: tdinovo who wrote (10133)	10/25/1997 9:47:00 PM
From: james	Read Replies (1) \| Respond to of 32384

Hi! tdinovo. I don't short stocks I've been working in biotech since I got a job, which is 15 years ago. I've seen lots of them going down, lots of them going nowhere, and a few of them make it. Drugs for metabolic diseases are extremely difficult to get through phase III, esp. for chronical usage. Its emphasis of longterm safety over efficacy kills >80% of them. If Ligand put 10 into trial (which only LLy can afford), and they all come from the same class but with different pharm. profile, I might change my mind. Nobody plays the market with 20% chance of one. You might know somemore details of their deal with LLY. I will glad to hear about it. In the world of drug development, Glaxo & Pfizer are held with the highest regarded, Merck & Ciga., are so good as anybody. Their goals are two drugs/year at the best. Have you checked LLY's pipeline lately. Quite empty! Even Bayer got involved with mAB against TNF-alpha for sepsis, & failured. Quite desperated!